SEATTLE, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced that the United States Patent and Trademark Office (USPTO) has granted a new patent (U.S. Patent No. 12,071,391) directed to compositions comprising endoxifen (in free base or salt forms) and an enteric material in which at least 90 percent of the endoxifen is (Z)-endoxifen. The patent also covers methods of administering those compositions to patients. Atossa is a clinical stage ...

SEATTLE, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) today announced the appointment of Michael Parks as Vice President of Investor and Public Relations. Mr. Parks brings nearly 30 years of investor relations and corporate communications experience working globally within the biopharmaceutical and healthcare industries. He will oversee corporate, executive, and digital communications, investor relations, thought leadership, and branding for the Company. Atossa is a clinical st ...

药物研发 - 公司正在开发一种名为(Z)-endoxifen的新药物,用于预防和治疗乳腺癌以及其他乳腺疾病[91] - 公司已完成4项1期临床试验和2项2期临床试验,并建立了自己的临床制造能力[91] - 公司正在进行一项2期临床试验,评估(Z)-endoxifen对乳腺密度的剂量反应关系,预计2024年下半年获得主要数据[91] - 公司正在开展一项2期临床试验,评估(Z)-endoxifen作为乳腺癌原位癌(DCIS)的新辅助治疗[92] - 公司已获得FDA批准开展一项2期临床试验,评估(Z)-endoxifen作为绝经前ER+/HER2-乳腺癌的新辅助治疗[92] - 公司正在开展一项2期临床试验,评估(Z)-endoxifen与abemaciclib联合用于ER+/HER2-乳腺癌的新辅助治疗[92] - 公司已获得3项美国专利和1项国际专利,保护(Z)-endoxifen至2038年11月[91] 财务状况 - 公司正处于研发阶段,尚未开始销售任何产品,预计在开发和推出药品计划之前不会产生收入[93] - 公司于2024年6月1日签订了一份新的办公室租赁协议,每月租金为1千美元,为期12个月[93] - 公司的关键会计估计在2024年6月30日结束的6个月内未发生重大变化[94] - 公司在2024年6月30日三个月和六个月内没有收入和相关成本[95] - 研发费用总计下降4%和1%,主要是由于非现金股票激励费用减少[98] - 一般及行政费用总计下降13%和12%,主要是由于现金薪酬和非现金股票激励费用减少[102][103] - 利息收入增加0.1百万美元和0.4百万美元,主要是由于货币市场账户收益率提高[105] - 2024年6月30日,公司现金及现金等价物为79.5百万美元,预计未来12个月内有足够现金支持运营[107] - 公司未来资金需求将取决于药物研发、临床试验、知识产权维护等方面的支出[109][110]

财务状况 - 完成第二季度2024年财务业绩报告，现金余额为7950万美元，无债务[3] - 公司现金及现金等价物为7952.6万美元[20] - 公司总资产为8585.8万美元[20] - 公司总负债为569.6万美元[20] - 公司总股东权益为8016.2万美元[20] - 公司持有1710万美元的股权投资[20] 研发进展 - 完成80毫克剂量药代动力学运行队列的入组，并完成卡里斯玛-内奥司汀临床试验给药[2] - 在美国癌症研究协会年会上展示了40毫克剂量组在24周治疗后100%疾病控制率的数据[2] - 启动了与阿贝马司布联合用药的新临床试验，作为I-SPY 2内分泌优化试点方案的一部分[2] - 公司正在开展5项内奥司汀的II期临床试验[16] - 内奥司汀是一种高效的选择性雌激素受体调节剂，具有抑制雌激素受体和降解雌激素受体的作用[15][16] 费用管控 - 研发费用同比下降4%，主要由于股份支付费用减少[5][7] - 管理费用同比下降13%，主要由于股份支付费用和薪酬开支减少[9][10] 其他 - 获得罗素3000指数成分股[3] - 任命Heather Rees为首席财务官[3] - 公司本季度净亏损为1192.7万美元[21] - 公司本季度每股基本及稀释亏损为0.10美元[21] - 公司本季度加权平均股数为12552.5万股[21]

Presented data showing 100% disease control rate after 24-week treatment with (Z)-Endoxifen in 40mg cohort of Phase 2 EVANGELINE study at the American Association for Cancer Research (AACR) Annual Meeting Completed enrollment in 80mg PK Run-in Cohort for EVANGELINE trial Completed Phase 2 Karisma-Endoxifen clinical trial dosing Updated protocol for (Z)-Endoxifen and abemaciclib clinical trial Ended second quarter 2024 with $79.5 million in cash and cash equivalents and no debt SEATTLE, Aug. 12, 2024 (GLOBE ...

SEATTLE, July 22, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the "Company") today announced that the 12-patient 80mg pharmacokinetic (PK) run-in cohort of the Phase 2 EVANGELINE (Endoxifen Versus exemestANe GosEreLIn) study has fully enrolled. EVANGELINE is a randomized non-inferiority trial of Atossa's patented Selective Estrogen Receptor Modulator (SERM), (Z)-endoxifen, and exemestane plus goserelin as a neoadjuvant treatment for pre-menopausal women with Grade 1 or 2 Es ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Atossa Genetics Inc. (ATOS) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.Atossa Genetics Inc. is a member of the Medical sector. This group includes 1026 individual stocks and currently holds a Zacks Sector Rank of #5. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring t ...

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

SEATTLE, July 02, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced the appointment of Heather Rees as the Company’s new Chief Financial Officer (CFO). Ms. Rees most recently served as Atossa’s Senior Vice President of Finance and Principal Accounting Officer. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer. Ms. Rees brings alm ...

SEATTLE, July 02, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced the appointment of Heather Rees as the Company’s new Chief Financial Officer (CFO). Ms. Rees most recently served as Atossa’s Senior Vice President of Finance and Principal Accounting Officer. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer. Ms. Rees brings alm ...